Antimicrobial resistance is a growing problem among pathogens from respiratory tract
infections. β-Lactam resistance rates are escalating among Streptococcus pneumoniae and Haemophilus influenzae [
[1]
]. Macrolides are increasingly used for the treatment of respiratory tract infections,
but their utility is compromised by intrinsic and acquired resistance. This review
analyses macrolide-resistance mechanisms and their worldwide distributions in S pneumoniae, S pyogenes, and H influenzae.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.J Antimicrob Chemother. 2003; 52: 229-246
- Observations on mode of action of erythromycin.Proc Soc Exp Biol Med. 1952; 81: 188-193
- Resistance of bacteria to erythromycin.Proc Soc Exp Biol Med. 1952; 81: 183-188
- Cross resistance to antibiotics: effect of exposures of bacteria to carbomycin or erythromycin in vitro.Proc Soc Exp Biol Med. 1952; 81: 725-729
- Development of resistance and cross-resistance in vitro to erythromycin, carbomycin, spiramycin, oleandomycin and streptogramin.Proc Soc Exp Biol Med. 1956; 93: 388-393
- Some chemical and stereochemical modifications of the erythromycin lactone rings.J Org Chem. 1974; 39: 2495-2501
- Les antibiotiques; structure et exemples de mode d'action.Hermann, Paris1973
- A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin.Antimicrob Agents Chemother. 1998; 42: 1392-1396
- The development of macrolides: clarithromycin in perspective.J Antimicrob Chemother. 1991; 27: 1-9
- Comparison of the acid stability of azithromycin and erythromycin A.J Antimicrob Chemother. 1990; 25: 39-47
- Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA.Biochimie. 1987; 69: 879-884
- Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes.Antimicrob Agents Chemother. 1982; 21: 811-818
- Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells.Curr Microbiol. 1995; 30: 273-279
- Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria.Antimicrob Agents Chemother. 1991; 35: 1273-1276
- 3D structure of AcrB: the archetypal multidrug efflux transporter of Escherichia coli likely captures substrates from periplasm.Drug Resist Updat. 2003; 6: 9-13
- Molecular basis of antimicrobial resistance in non-typable Haemophilus influenzae.Microbiologia. 1997; 13: 309-314
- The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump.J Bacteriol. 1997; 179: 6855-6857
- Erythromycin-inducible resistance in Staphylococcus aureus: requirements for induction.J Bacteriol. 1971; 106: 835-847
- Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin.J Antimicrob Chemother. 1999; 43: 559-562
- Insights into erythromycin action from studies of its activity as inducer of resistance.Antimicrob Agents Chemother. 1995; 39: 797-805
- Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A).Antimicrob Agents Chemother. 2003; 47: 2699-2702
- A complex attenuator regulates inducible resistance to macrolides, lincosamides, and streptogramin type B antibiotics in Streptococcus sanguis.J Bacteriol. 1983; 154: 1252-1262
- Constitutive expression of erythromycin resistance mediated by the ermAM determinant of plasmid pAM beta 1 results from deletion of 5′ leader peptide sequences.Plasmid. 1987; 18: 250-253
- Nucleotide sequence of ermA, a macrolide-lincosamide-streptogramin B determinant in Staphylococcus aureus.J Bacteriol. 1985; 162: 633-640
- Naturally occurring Staphylococcus epidermidis plasmid expressing constitutive macrolide-lincosamide-streptogramin B resistance contains a deleted attenuator.J Bacteriol. 1986; 166: 479-483
- A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes.Antimicrob Agents Chemother. 1998; 42: 257-262
- Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece.Antimicrob Agents Chemother. 2001; 45: 342-344
- Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.Antimicrob Agents Chemother. 1996; 40: 477-480
- Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare.Antimicrob Agents Chemother. 1994; 38: 381-384
- Genetic basis of macrolide and lincosamide resistance in Brachyspira (Serpulina) hyodysenteriae.FEMS Microbiol Lett. 1999; 172: 255-260
- A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre.Mol Microbiol. 1999; 31: 633-639
- Mutations in domain II of 23 S rRNA facilitate translation of a 23 S rRNA-encoded pentapeptide conferring erythromycin resistance.J Mol Biol. 1996; 259: 1-6
- Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA.J Mol Biol. 1999; 289: 827-834
- The extended loops of ribosomal proteins L4 and L22 are not required for ribosome assembly or L4-mediated autogenous control.RNA. 2003; 9: 1188-1197
- Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations.J Antimicrob Chemother. 2002; 49: 935-939
- The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22.Mol Cell. 2001; 8: 181-188
- Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli.J Bacteriol. 1994; 176: 6192-6198
- Multidrug resistance mechanisms: drug efflux across two membranes.Mol Microbiol. 2000; 37: 219-225
- Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family.Mol Microbiol. 1990; 4: 1207-1214
- Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes.Mol Microbiol. 1996; 22: 867-879
- mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.Antimicrob Agents Chemother. 1997; 41: 2251-2255
- Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.Antimicrob Agents Chemother. 2003; 47: 1017-1022
- Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.Antimicrob Agents Chemother. 2000; 44: 2118-2125
- Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.Antimicrob Agents Chemother. 2002; 46: 125-131
- High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.J Antimicrob Chemother. 2003; 52: 345-353
- Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.Antimicrob Agents Chemother. 2000; 44: 3395-3401
- Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.Antimicrob Agents Chemother. 2002; 46: 2963-2968
- Ribosomal mutations in Streptococcus pneumoniae clinical isolates.Antimicrob Agents Chemother. 2002; 46: 654-658
- Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999–2000 study.Antimicrob Agents Chemother. 2003; 47: 1777-1783
- Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae.Antimicrob Agents Chemother. 2001; 45: 319-323
- Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation.Diagn Microbiol Infect Dis. 2002; 43: 163-165
- Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy.Clin Infect Dis. 2003; 36: e19-e25
- Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis.Clin Microbiol Infect. 2003; 9: 966-969
- Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 Central and Eastern European countries.Antimicrob Agents Chemother. 2002; 46: 371-377
- Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany.Antimicrob Agents Chemother. 2003; 47: 2319-2322
- Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.Antimicrob Agents Chemother. 2003; 47: 2696-2698
- Emergence of macrolide resistance during treatment of pneumococcal pneumonia.N Engl J Med. 2002; 346: 630-631
- Emergence of group A streptococcus strains with different mechanisms of macrolide resistance.Antimicrob Agents Chemother. 2002; 46: 1199-1203
- In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.Antimicrob Agents Chemother. 2002; 46: 2956-2962
- Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999–2000.J Chemother. 2003; 15: 226-234
- Antibiotic consumption and resistance selection in Streptococcus pneumoniae.J Antimicrob Chemother. 2002; 50: 27-37
- Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001.South Med J. 2003; 96: 974-985
- Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.Antimicrob Agents Chemother. 2003; 47: 1867-1874
- Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers.Clin Microbiol Infect. 2003; 9: 653-661
- Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program.J Chemother. 2003; 15: 107-112
- Prevalence of antimicrobial resistance in Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes: results of a multicentre study in Turkey.Int J Antimicrob Agents. 2002; 19: 207-211
- Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000–2001.Antimicrob Agents Chemother. 2003; 47: 489-493
- Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999–2001).Diagn Microbiol Infect Dis. 2003; 45: 273-278
- Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.Antimicrob Agents Chemother. 2003; 47: 2152-2157
- Macrolide resistance and distribution of erm and mef genes among beta-haemolytic streptococci in Hong Kong.Eur J Clin Microbiol Infect Dis. 2002; 21: 238-240
- Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive Streptococcus pneumoniae invasive isolated from children in the Ille de France area.Eur J Clin Microbiol Infect Dis. 2004; 23: 27-33
- Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995–1996 cold season.J Antimicrob Chemother. 1998; 41: 411-415
- Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities.Antimicrob Agents Chemother. 2001; 45: 627-629
- Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin.J Antimicrob Chemother. 2002; 50: 403-406
- Mechanisms of macrolide resistance in clinical pneumococcal isolates in France.Antimicrob Agents Chemother. 2001; 45: 636-638
- Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999–2000 study.J Antimicrob Chemother. 2002; 50: 39-47
- Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001.Antimicrob Agents Chemother. 2003; 47: 2370-2372
- Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.Antimicrob Agents Chemother. 1999; 43: 2144-2147
- Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–01.J Infect. 2004; 48: 56-65
- In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities.Clin Microbiol Infect. 2003; 9: 704-707
- High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.J Antimicrob Chemother. 2000; 45: 605-609
- Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy.Antimicrob Agents Chemother. 2002; 46: 3987-3990
- Low rates of antimicrobial resistance in respiratory pathogens from a pediatric population in north-eastern Italy.Pediatr Med Chir. 2003; 25: 131-134
- High prevalence of erythromycin resistance of Streptococcus pyogenes in Greek children.Pediatr Infect Dis J. 2001; 20: 863-868
- Genetic and phenotypic characterization of macrolide resistance in group A streptococci isolated from adults with pharyngo-tonsillitis in France.J Antimicrob Chemother. 2001; 48: 291-294
- The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.J Infect Chemother. 2001; 7: 81-86
- Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance.Antimicrob Agents Chemother. 1999; 43: 48-52
- Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates.J Antimicrob Chemother. 2000; 45: 167-173
- Macrolide resistance determinants of group A streptococci in Ankara, Turkey.J Antimicrob Chemother. 2003; 52: 110-112
- Genetic and phenotypic characterization of resistance to macrolides in Streptococcus pyogenes from Argentina.Int J Antimicrob Agents. 2004; 23: 95-98
- Antimicrobial susceptibility and survey of macrolide resistance mechanisms among Streptococcus pyogenes isolated in Rio de Janeiro, Brazil.Microb Drug Resist. 2003; 9: 87-91
- Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes.Pediatr Infect Dis J. 2003; 22: 623-627
- Macrolide-resistant Streptococcus pneumoniae in Canada during 1998–1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.Antimicrob Agents Chemother. 2001; 45: 2147-2150
- Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.Clin Microbiol Infect. 2004; 10: 27-36
- Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.Pediatr Infect Dis J. 2000; 19: 95-104
- Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.Antimicrob Agents Chemother. 2000; 44: 43-50
- Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae.Antimicrob Agents Chemother. 2003; 47: 405-407
- Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe.Clin Microbiol Infect. 2003; 9: 741-745
- Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin.J Antimicrob Chemother. 2002; 50: 403-406
- Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries. Laser Study Group.Int J Antimicrob Agents. 2000; 16: 17-24
- Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999–2000).Braz J Infect Dis. 2003; 7: 44-61
- Antibiotic resistance of pneumococci in Norway.Int J Antimicrob Agents. 1998; 10: 77-81
- Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995–1996 cold season.J Antimicrob Chemother. 1998; 41: 411-415
- Antimicrobial resistance of invasive pneumococci in Finland in 1999–2000.Antimicrob Agents Chemother. 2003; 47: 1832-1835
- Antibiotic susceptibility and serotypes of Streptococcus pneumoniae isolates from Hungary.J Antimicrob Chemother. 2003; 51: 887-893
- Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program.J Chemother. 2003; 15: 107-112
- In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.Clin Microbiol Infect. 2003; 9: 590-599
- National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.J Clin Pathol. 2003; 56: 344-347
- Patterns of antibiotic resistance, serotype distribution, and patient demographics of Streptococcus pneumoniae in Hong Kong.Chemotherapy. 2001; 47: 110-116
- Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.J Antimicrob Chemother. 2003; 52: 944-952
- Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe.Clin Microbiol Infect. 2003; 9: 741-745
- Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.Antimicrob Agents Chemother. 2002; 46: 546-549
- Macrolide resistance phenotypes in Streptococcus pneumoniae in Santiago, Chile.Int J Antimicrob Agents. 2002; 20: 108-112
- PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea.Int J Antimicrob Agents. 2004; 23: 44-51
- Prevalence of erm(A) and mef(B) erythromycin resistance determinants in isolates of Streptococcus pneumoniae from New Zealand.J Antimicrob Chemother. 2002; 50: 597-599
- Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.J Clin Microbiol. 2003; 41: 428-431
- Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy.Antimicrob Agents Chemother. 2002; 46: 3987-3990
Article info
Identification
Copyright
© 2004 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
